Katrina Abuabara

Katrina Abuabara

Auto-generated profile, based on publicly available information

Katrina Abuabara

Department of Dermatology, University of California San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2010 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KAK Abuabara
K Abuabara
RAR.S Azfar
R.S Azfar
DSD.B Shin
D.B Shin
ANA.L Neimann
A.L Neimann
ATA.B Troxel
A.B Troxel
JGJ.M Gelfand
J.M Gelfand

1 June 2014 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
JMJacob S. Margolis
Jacob S. Margolis
KAKatrina Abuabara
Katrina Abuabara
WBWarren Bilker
Warren Bilker
OHOle Hoffstad
Ole Hoffstad
DMDavid J. Margolis
David J. Margolis
Atopic dermatitis (AD) or eczema is a common skin disease that often begins in early childhood.1-7 It begins before the second year of life, has a waxing and waning clinical course, and is often reported to resolve soon after the first decade of life.2 The etiology of AD is likely multifactorial resulting from a complex interaction between genetic and environmental factors.2-5 Little has been reported about the natural history of AD and how genetic and environmental factors are associated with its waxing and waning nature.7-11

1 May 2019 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
FRFaustine D. Ramirez
Faustine D. Ramirez
SCShelley Chen
Shelley Chen
SLSinéad M. Langan
Sinéad M. Langan
APAric A. Prather
Aric A. Prather
CMCharles E. McCulloch
Charles E. McCulloch
KAKatrina Abuabara
Katrina Abuabara
Atopic dermatitis ranks among the largest components of the nonfatal disease burden worldwide.1 Sleep disturbances have been identified as central to quality-of-life decrements in atopic dermatitis,2,3 but little is known about their association with sleep in the general population. Pruritus, a hallmark of atopic dermatitis, is often worst at night, resulting in scratching that may interfere with the process of falling asleep and cause disruptions in ongoing sleep.4,5 Small polysomnography and actigraphy studies among clinic-based populations have found that children with atopic dermatitis are more restless in their sleep, awaken more often, and spend more time awake after the onset of sleep.6-10 Adequate sleep is critical to well-being and health; in children, acute and chronic sleep disturbances have been associated with a wide range of cognitive, mood, and behavioral impairments and have been linked to poor educational performance.11-13

24 November 2017 in Allergy
Verified
Journal Article
Open access
PDF file
KAK. Abuabara
K. Abuabara
AYA. M. Yu
A. M. Yu
JOJ.‐P. Okhovat
J.‐P. Okhovat
IAI. E. Allen
I. E. Allen
SLS. M. Langan
S. M. Langan
Background: There are sparse and conflicting data regarding the long‐term clinical course of atopic dermatitis (AD). Although often described as a childhood disease, newer population‐based estimates suggest the prevalence of pediatric and adult disease may be similar.Methods: Our objective was to determine whether there is a decline in the prevalence of AD in population‐based cohorts of patients followed longitudinally beyond childhood. We conducted a systematic review and meta‐analysis including studies assessing AD prevalence across 3 or more points in time. The primary outcome was weighted overall risk difference (percentage decrease in AD prevalence).Results: Of 2080 references reviewed, 7 studies with 13 515 participants were included. Participants were assessed at 3‐6 time points, ranging from age 3 months to 26 years. The percentage decrease in prevalence after age 12 was 1%, which was not significantly different from zero (95% confidence interval −2%‐5%). Similar results were found with other age cut‐offs.Conclusion: The prevalence of AD in longitudinal birth cohort studies is similar in childhood and adolescence/early adulthood.

1 June 2011 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
EDErica D. Dommasch
Erica D. Dommasch
KAKatrina Abuabara
Katrina Abuabara
DSDaniel B. Shin
Daniel B. Shin
JNJosephine Nguyen
Josephine Nguyen
ATAndrea B. Troxel
Andrea B. Troxel
JGJoel M. Gelfand
Joel M. Gelfand

19 July 2016 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JCJ.R. Chalmers
J.R. Chalmers
ESE. Simpson
E. Simpson
CAC.J. Apfelbacher
C.J. Apfelbacher
KTK.S. Thomas
K.S. Thomas
LKL. Kobyletzki
L. Kobyletzki
PSP.I. Spuls
P.I. Spuls
This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient‐reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient‐reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient‐reported symptoms were discussed [including the Patient‐Oriented SCOring Atopic Dermatitis index, Patient‐Oriented Eczema Measure (POEM), Self‐Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient‐reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms.